317 related articles for article (PubMed ID: 30915522)
1. Clinical impact of [
Leuzy A; Savitcheva I; Chiotis K; Lilja J; Andersen P; Bogdanovic N; Jelic V; Nordberg A
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1276-1286. PubMed ID: 30915522
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
3. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic impact of [
Zwan MD; Bouwman FH; Konijnenberg E; van der Flier WM; Lammertsma AA; Verhey FR; Aalten P; van Berckel BN; Scheltens P
Alzheimers Res Ther; 2017 Jan; 9(1):2. PubMed ID: 28093088
[TBL] [Abstract][Full Text] [Related]
5. Is there a difference in regional read [
Farrar G; Molinuevo JL; Zanette M
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1299-1308. PubMed ID: 30863934
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic.
Müller EG; Edwin TH; Stokke C; Navelsaker SS; Babovic A; Bogdanovic N; Knapskog AB; Revheim ME
PLoS One; 2019; 14(8):e0221365. PubMed ID: 31430334
[TBL] [Abstract][Full Text] [Related]
7. Relationship between
Hammers DB; Atkinson TJ; Dalley BC; Suhrie KR; Beardmore BE; Burrell LD; Horn KP; Rasmussen KM; Foster NL; Duff K; Hoffman JM
Clin Neuropsychol; 2017 Apr; 31(3):531-543. PubMed ID: 28077020
[TBL] [Abstract][Full Text] [Related]
8. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
9. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
10. Impact of molecular imaging on the diagnostic process in a memory clinic.
Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
[TBL] [Abstract][Full Text] [Related]
11. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
[TBL] [Abstract][Full Text] [Related]
12. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
[TBL] [Abstract][Full Text] [Related]
13. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes up to 9 years after [
Collij LE; Farrar G; Zwan M; van de Giessen E; Ossenkoppele R; Barkhof F; Rozemuller AJM; Pijnenburg YAL; van der Flier WM; Bouwman F
Alzheimers Res Ther; 2023 Nov; 15(1):207. PubMed ID: 38012799
[TBL] [Abstract][Full Text] [Related]
15. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
16. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
17. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
[TBL] [Abstract][Full Text] [Related]
18. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
[TBL] [Abstract][Full Text] [Related]
19. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
20. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
